North Dakota is currently home to 231 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Fargo, Bismarck, Grand Forks and Minot. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NCT04333537
Recruiting
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nod... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Sanford Broadway Medical Center, Fargo, North Dakota
Conditions: Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Register for Updates
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265
Recruiting
This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/03/2024
Locations: Sanford Bismarck Medical Center, Bismarck, North Dakota
Conditions: Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
Register for Updates
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
NCT06005974
Recruiting
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.
Gender:
All
Ages:
55 years and above
Trial Updated:
02/02/2024
Locations: Sanford Health - Fargo, Fargo, North Dakota
Conditions: AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor
Register for Updates
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
NCT04296864
Recruiting
This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Tracie Malsom, Fargo, North Dakota
Conditions: Atopic Keratoconjunctivitis
Register for Updates
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Recruiting
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Sanford Bismarck Medical Center, Bismarck, North Dakota
Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Register for Updates
Midwest Birth Outcomes and Indigenous American Pregnancy
NCT06008561
Recruiting
Indigenous American pregnancies in the Midwest have disproportionally high rates of adverse outcomes, however little research has been done on how historical trauma and stress may impact these adverse outcomes. This project gathers data from pregnant Indigenous American women on their experiences with historical trauma, stress, and birth outcomes, as well as physiological data of how they respond to stress, in order to better understand the associations between these factors and the biological m... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Sanford Health, Fargo, North Dakota
Conditions: Pregnancy
Register for Updates
Beverages for Thought: Exploring the Relationship Between Blood Glucose and Cognition
NCT05888779
Recruiting
The objective of this study is to conduct novel research on the relationship between blood sugar and cognition.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/09/2024
Locations: USDA Grand Forks Human Nutrition Research Center, Grand Forks, North Dakota
Conditions: Overweight
Register for Updates
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225
Recruiting
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 recept... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Sanford Broadway Medical Center, Fargo, North Dakota
Conditions: Endometrial Serous Adenocarcinoma, Uterine Corpus Carcinosarcoma
Register for Updates
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and s... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
01/09/2024
Locations: Sanford Bismarck Medical Center, Bismarck, North Dakota
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NCT04588246
Recruiting
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is impo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Sanford Bismarck Medical Center, Bismarck, North Dakota
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
NCT04880031
Recruiting
This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/04/2024
Locations: Lillestol Research LLC, Fargo, North Dakota
Conditions: Nonalcoholic Steatohepatitis (NASH)
Register for Updates
Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12
NCT05454189
Recruiting
Implanted port devices (IPD) play an essential role in the safe administration of cancer treatments by providing a device to safely administer caustic chemotherapy agents. The current recommended frequency of flushing the IPD per manufacturers guidelines is every 4-6 weeks. The purpose of this study is to find out if extending IPD flushes to every 12 weeks is safe and if it is just as effective as every 4 week flushing.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/29/2023
Locations: Essentia Health Fargo, Fargo, North Dakota
Conditions: Maintenance of Implanted Port Devices
Register for Updates